Combined Arimidex and Herceptin – pro
Herceptin and Arimidex are being used in combination, for which there is some supporting literature. TAnDEM was the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptorcopositive metastatic breast cancer (MBC). It concluded that Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptorcopositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination. It is not recommended by NCCN.
I do not find current trials f this combination, but one study needs to be confirmed and, therefore, more trials are needed, and I consider this combination to be E/I.
Bella Kaufman et al, Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2Positive, Hormone ReceptorPositive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study. Journal of Clinical Oncology 27, no. 33 (November 2009) 5529-5537.
A. Jones, Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: what can be expected and why? Ann Oncol (2003) 14 (12): 1697-1704.
J. Gavilá et al, SEOM clinical guidelines in metastatic breast cancer 2015.n Transl Oncol. 2015; 17: 946955.
NCCN, BINV -N 2017